

## **EUROPEAN PATENT GRANTED AND VALIDATED FOR CORE BREAST AND OVARIAN CANCER PATENT FAMILY**

- **Key European Patent validated covering a diagnostic test kit for breast or ovarian cancer**
- **BARD1-Ovarian and BARD1-Breast cancer tests now protected by important patents in US and European marketplaces**

**Melbourne, Australia, 10 August 2020:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 or Company**), a medical diagnostics company, announced that it has received confirmation that validation has been completed for granted European Patent number 2619218 titled “Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof”.

European Patent (EP) number 2619218 was granted by the EPO on 29 April 2020. EP patents are not enforceable until validation has been completed in the designated countries. EP261918 has now been validated in France, Germany, Italy, Spain, Switzerland and United Kingdom, providing enforceable IP protection in these European countries.

The issued EP 2619218 claims are directed to kits comprising peptides from BARD1 isoforms for detecting autoantibodies associated with breast or ovarian cancer. The patent application was filed on 23 September 2011 and is due to expire on 23 September 2031.

BARD1 CEO Dr Leearne Hinch said: “This core patent family provides intellectual property protection in the US and Europe for our BARD1-Ovarian and BARD1-Breast cancer tests in development for early detection of ovarian and breast cancers.”

The BARD1-Ovarian test is in development for early detection of ovarian cancer in high-risk women with Hereditary Breast Ovarian Cancer (HBOC). Ovarian cancer was the seventh most common cancer in women, the leading cause of gynaecological cancer death, and was responsible for 5% of all female cancer deaths worldwide with 295,414 new cases and 184,799 deaths in 2018. There is currently no screening test recommended for ovarian cancer, which is often diagnosed at a late-stage after symptoms have occurred. The 5-year survival rate of the disease is only 47%.

The Company is also developing the BARD1-Breast test for early detection of breast cancer in average and/or high-risk women with HBOC. Breast cancer is the second most commonly diagnosed cancer and leading cause of cancer death in women worldwide with 2.1 million new cases and 626,679 deaths in 2018. For women aged 40 - 74 who participate in screening every 1 - 2 years, the 5-year survival rate is approximately 90% due to mammography screening, increased awareness and improved treatments. However, mammography screening can cause harm through exposure to radiation, false-positive test results and overdiagnosis of biologically benign lesions.

*Authorised for release by Company Secretary, Tony Di Pietro.*

- ENDS -

### **COMPANY CONTACTS:**

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-Executive Chairman  
E [geoff@bard1.com](mailto:geoff@bard1.com)  
M +61 417 203 021

## ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or **Company**) is a leading Australian-based medical diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on the development and commercialisation of best in class lifesaving diagnostic solutions for health care professionals and patients. The cancer diagnostics portfolio includes the marketed hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

## FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.